Home › Trial NCT03841565
Daratumumab, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma
- Trial IDNCT03841565
- StatusWithdrawn
- PhasePhase 2
- Study typeInterventional
- SponsorAcademic and Community Cancer Research United
- Enrollment—
- Start date2020-08-07
- ConditionsRecurrent Plasma Cell Myeloma
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.